Drug intelligence / Profile preview

anti-PD-1 antibody + mFOLFIRINOX

Development stage: Unknown
Lead developer: Zhejiang University
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

anti-PD-1 antibody + mFOLFIRINOX is a combination chemo-immunotherapy regimen being evaluated for the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). The regimen combines an anti-Programmed Cell Death Protein 1 (PD-1) monoclonal antibody, which serves as an immune checkpoint inhibitor to enhance T-cell activity against tumor cells, with the modified FOLFIRINOX (mFOLFIRINOX) chemotherapy backbone. mFOLFIRINOX consists of oxaliplatin (a DNA alkylating agent), irinotecan (a topoisomerase I inhibitor), and 5-fluorouracil (a thymidylate synthase inhibitor) modulated by leucovorin. This combination is primarily being developed and studied by Zhejiang University in randomized clinical trials to determine if the addition of immunotherapy can improve the poor prognosis associated with metastatic pancreatic cancer compared to standard-of-care chemotherapy alone.

Other names: anti-PD-1 antibody-Zhejiang University-pancreatic ductal adenocarcinomaanti-PD1 antibody-Zhejiang University-pancreatic ductal adenocarcinomaanti-PD 1 antibody-Zhejiang University-pancreatic ductal adenocarcinomaAnti-PD-1 Antibody plus mFOLFIRINOXAnti-PD1 Antibody plus mFOLFIRINOXAnti-PD 1 Antibody plus mFOLFIRINOXmFOLFIRINOX + Anti-PD-1 antibody

Targets

TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)PDCD1 (Programmed cell death protein 1 receptor)DNA

Beyond the preview

Go deeper on anti-PD-1 antibody + mFOLFIRINOX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-PD-1 antibody + mFOLFIRINOX.

Explore the full profile